Every material Form 8-K IGC Pharma, Inc. has filed with the SEC since June 08, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
IGC Pharma furnished an updated investor presentation dated July 2026 under Regulation FD, filed as Exhibit 99.1 to a Form 8-K dated July 13, 2026. The presentation covers the Phase 2 CALMA trial of IGC-AD1 for agitation in Alzheimer's dementia, which the filing describes as investigational and not approved by the FDA, and it presents illustrative valuation scenarios that the company says are hypothetical and not forecasts.
The CALMA Phase 2 trial has a target of 146 participants, and the presentation says more than 80% have completed dosing.
The presentation cites a current valuation of about $30 million as of July 10, 2026, with illustrative post-Phase 2 scenarios of $350 million to $750 million over 4 to 9 months.
Blinded pooled data show a mean change in CMAI of −13.6 at week 2 and −14.9 at week 6, which the company says cannot establish treatment effect or efficacy.
On June 30, 2026, IGC Pharma's CEO Ram Mukunda and principal financial officer Claudia Grimaldi bought company common stock at $0.27 per share. Payment was made by canceling amounts the company owed them, including personal cash advances, so no cash changed hands. The filing says the transaction reduced the company's obligations by $1,154,210 and increased stockholders' equity, while the new shares are restricted securities issued to insiders.
Mr. Mukunda received 2,226,475 shares in exchange for $601,148 of amounts owed, including about $283,639 of personal cash advances.
Ms. Grimaldi received 2,048,378 shares in exchange for $553,062 of amounts owed, including about $268,723 of personal cash advances.
The independent directors and Audit Committee approved the transactions in advance, with interested directors recused.
The shares were issued in private transactions under Section 4(a)(2) and are restricted securities; the filing was dated July 6, 2026.
IGC Pharma entered into an amendment on June 5, 2026 to extend its Master Loan and Security Agreement with O-Bank Co., Ltd. of Taiwan, keeping a maximum aggregate facility limit of $12,000,000. Apart from the facility fee rising from $48,000 to $60,000, the material terms are substantially unchanged from the June 24, 2025 facility letter, so the change is modest for shareholders.
Amendment dated June 5, 2026 extends the Master Loan and Security Agreement and General Banking Facility Letter with O-Bank Co., Ltd.
Maximum aggregate facility limit is $12,000,000.
Facility fee increases from $48,000 to $60,000.
Other material terms remain substantially unchanged from the 2025 facility letter.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every IGC Pharma, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →